Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 8, Issue 3, 2014, Pages 145-151

  Camara, Soumaïla ^a   Bouenizabila, Evariste ^b   Hermans, Michel P ^c   Ahn, Sylvie A ^c   Rousseau, Michel F ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Centre Hospitalier et Universitaire de Brazzaville   (Congo)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Glycated haemoglobin; LDL cholesterol; Microangiopathy; Quality of care; Systolic blood pressure; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ACHIEVEMENT; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; B LYMPHOCYTE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BELGIUM; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHENOTYPE;

AGED; BELGIUM; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-SECRETING CELLS; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK FACTORS;

EID: 84907762168     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2014.04.037     Document Type: Article

References (50)

1. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
2. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, and J.H. Stein Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
3. M.P. Hermans, S.A. Ahn, and M.F. Rousseau Residual vascular risk in T2DM: the next frontier M. Zimering, Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications 2011 InTech Rijeka, Croatia 45 66
4. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, and O. Wiklund ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
5. T.J. Anderson, J. Grégoire, R.A. Hegele, P. Couture, G.B. Mancini, and R. McPherson 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
6. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
7. F. Nobels, N. Debacker, C. Brotons, M. Elisaf, M.P. Hermans, and G. Michel Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus Cardiovasc Diabetol 10 2011 82
8. M.P. Hermans, C. Brotons, M. Elisaf, G. Michel, E. Muls, and F. Nobels Optimal type 2 diabetes mellitus management: the randomized controlled OPTIMISE benchmarking study: baseline results from six European countries Eur J Prev Cardiol 20 2013 1095 1105
9. M.P. Hermans, M. Elisaf, G. Michel, E. Muls, F. Nobels, and H. Vandenberghe for the OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee. Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes: The OPTIMISE randomized, controlled trial Diabetes Care 36 2013 3388 3395
10. G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, and M. Böhm 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
11. K. Pyorala, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, and G. Thorgeirsson Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
12. R.B. Goldberg, M.J. Mellies, F.M. Sacks, L.A. Moyé, B.V. Howard, and W.J. Howard Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators Circulation 98 1998 2513 2519
13. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
14. UK Prospective Diabetes Study (UKPDS) Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) Br Med J 317 1998 703 713
15. S.M. Haffner, C.M. Alexander, T.J. Cook, S.J. Boccuzzi, T.A. Musliner, and T.R. Pedersen Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study Arch Intern Med 159 1999 2661 2667
16. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group J Am Med Assoc 281 1999 2005 2012
17. A.I. Adler, I.M. Stratton, H.A. Neil, J.S. Yudkin, D.R. Matthews, and C.A. Cull Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study Br Med J 321 2000 412 419
18. I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, and C.A. Cull Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study Br Med J 321 2000 405 412
19. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 165 2005 1410 1419
20. Cholesterol Treatment Trialists' (CTT) Collaborators, P.M. Kearney, L. Blackwell, R. Collins, A. Keech, and J. Simes Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
21. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, and J.B. Buse Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
22. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
23. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
24. K.K. Ray, S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, and D. Preiss Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
25. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
26. M.T. Czarnecki Benchmarking: a data-oriented look at improving health care performance J Nurs Care Qual 10 1996 1 6
27. R. Valdez, J.C. Seidell, Y.I. Ahn, and K.M. Weiss A new index of abdominal adiposity as an indicator of risk for cardiovascular disease. A cross-population study Int J Obes Relat Metab Disord 17 1993 77 82
28. K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, and K.A. Donato Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
29. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
30. M.P. Hermans, S.A. Ahn, and M.F. Rousseau Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males Cardiovasc Diabetol 9 2010 88
31. M.P. Hermans, S.A. Ahn, and M.F. Rousseau The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk. β-cell function loss and microangiopathy in type 2 diabetes females Lipids Health Dis 11 2012 132
32. M.P. Hermans, J. Levy, R.J. Morris, and R.C. Turner Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes Diabetologia 42 1999 678 687
33. M.P. Hermans, J. Levy, R.J. Morris, and R.C. Turner Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes Diabetes 48 1999 1779 1786
34. M.P. Hermans Diabetic macro- and microvascular disease in type 2 diabetes Diabetes Vasc Dis Res 4 2007 S7 S11
35. Th. Munoko, and M.P. Hermans Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort Diabetes Metab Syndr 2 2008 115 124
36. R.J. Stevens, R.L. Coleman, A.I. Adler, I.M. Stratton, D.R. Matthews, and R.R. Holman UKPDS 66 risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes Diabetes Care 27 2004 201 207
37. I. Simera, D. Moher, J. Hoey, K.F. Schulz, and D.G. Altman A catalogue of reporting guidelines for health research Eur J Clin Invest 40 2010 35 53
38. M.K. Ali, K.M. Bullard, J.B. Saaddine, C.C. Cowie, G. Imperatore, and E.W. Gregg Achievement of goals in U.S. diabetes care, 1999-2010 N Engl J Med 368 2013 1613 1624
39. M.E. Farkouh, W.E. Boden, V. Bittner, V. Muratov, P. Hartigan, and M. Ogdie Risk factor control for coronary artery disease secondary prevention in large randomized trials J Am Coll Cardiol 61 2013 1607 1615
40. P. Gaede, and O. Pedersen Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes Ann Med 36 2004 355 366
41. V. Andros, A. Egger, and U. Dua Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes J Manag Care Pharm 12 2006 303 309
42. M.P. Hermans, K.D. Amoussou-Guenou, S.A. Ahn, M.F. Rousseau, L. Everaert, and A. Aerts The elusive type 2 diabetes individual at blood pressure control: a phenotypic characterization of goal-achieving patients Diabetes Metab Syndr 4 2010 215 219
43. M.P. Hermans, M. Castro Cabezas, T. Strandberg, J. Ferrières, J. Feely, and M. Elisaf Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries Curr Med Res Opin 26 2010 445 454
44. M.P. Hermans, and J.C. Fruchart Reducing vascular events risk in patients with dyslipidemia: an update for clinicians Ther Adv Chronic Dis 2 2011 307 323
45. F. McCrate, M. Godwin, and L. Murphy Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's Nfld Can Fam Physician 56 2010 e13 e19
46. M.P. Hermans, S.A. Ahn, and M.F. Rousseau The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes J Diabetes Complications 26 2012 187 194
47. L.S. Phillips, W.T. Branch, C.B. Cook, J.P. Doyle, I.M. El-Kebbi, and D.L. Gallina Clinical inertia Ann Intern Med 135 2001 825 834
48. A.J. Owen, C. Retegan, M. Rockell, G. Jennings, and C.M. Reid Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes Clin Exp Pharmacol Physiol 36 2009 643 647
49. M. Serrano-Gil, and S. Jacob Engaging and empowering patients to manage their type 2 diabetes. Part 1: a knowledge, attitude, and practice gap? Adv Ther 27 2010 321 333
50. S.A. Nelson, G.K. Dresser, and M.K. Vandervoort Barriers to blood pressure control: a STITCH substudy J Clin Hypertens (Greenwich) 13 2011 73 80